San Francisco startup Structure Therapeutics is additionally engaged on an oral, when-daily GLP-1 drug termed GSBR-1290—the drug surpassed Wall Avenue’s expectations in June each time a mid-phase research showed average weight loss of about 6% and it options to start An additional mi